Crohn's Disease Pipeline and Product Under Development, H1 2015

This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects.

Some of the Company profiles mentioned in this report are Alba Therapeutics Corporation, Ampio Pharmaceuticals, Bristol-Myers Squibb Company, Genor BioPharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Sigmoid Pharma Limited, Teva Pharmaceutical Industries Limited, Winston Pharmaceuticals, Trino Therapeutics Limited, Mesoblast Limited.

Get a copy of this report at . (This is a premium report price at US$2000 for a single user PDF license)


- The report provides a snapshot of the global therapeutic landscape of Crohn's Disease

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.